A single psychedelic experience, paired with structured therapy, may dramatically improve a smoker’s chances of quitting, outperforming the most widely used treatments on the market.
This is the central finding of a new randomized clinical trial from researchers at Johns Hopkins University, where scientists directly compared psilocybin, the psychoactive substance found in so-called “magic mushrooms,” to standard nicotine patch therapy.
The results suggest that, despite decades of reliance on nicotine replacement, a fundamentally different approach to addiction treatment may be emerging.
Published in JAMA Network Open, the study offers some of the strongest evidence yet that psychedelic-assisted therapy can reshape how clinicians think about addiction, by targeting not merely the physical habit, but the psychological framework that sustains it.
“Smoking is among the leading causes of premature death, with approximately 8 million deaths annually, including approximately 480,000 in the US,” researchers write. “Most smoking cessation interventions result in modest long-term success. More than two-thirds of US smokers want to quit, indicating an unmet need warranting novel approaches.”
Smoking remains one of the leading causes of preventable death worldwide. Even among smokers who actively want to quit, relapse rates remain stubbornly high, with many traditional treatments frequently failing within months.
The new study set out to test whether psilocybin, administered in a controlled therapeutic setting, may present a more durable solution.
Researchers recruited 82 adult smokers, all of whom had previously tried and failed to quit. Participants were randomly assigned to one of two groups. One group received a single high dose of psilocybin alongside a 13-week course of cognitive behavioral therapy (CBT), and the other group underwent a standard nicotine patch regimen combined with the same therapy.
At the six-month mark, the difference between the two groups was striking.
Among those who received psilocybin, 40.5% achieved prolonged smoking abstinence, compared to just 10% in the nicotine patch group. In another key measure, whether participants had abstained from smoking in the previous week, 52.4% of the psilocybin group remained smoke-free, compared to 25% of those using nicotine patches.
Statistically, that translates to more than six times greater odds of long-term abstinence for those receiving psilocybin.
While nicotine replacement therapies have long been considered a bedrock of smoking cessation, their real-world effectiveness has often been modest. The findings from this study suggest that a radically different mechanism, one that operates through psychological insight rather than chemical substitution, may hold greater promise.
Unlike nicotine patches, which aim to reduce withdrawal symptoms by delivering controlled doses of nicotine, psilocybin does not directly target the biological pathways of addiction. Instead, researchers believe it may work by altering how individuals perceive themselves and their habits.
Participants in the psilocybin group underwent extensive preparation before the dosing session, including guided discussions about their relationship with smoking.
During the session itself, they were encouraged to focus inward, often lying down with eyeshades and listening to music as the drug’s effects unfolded. In the weeks that ensued, therapy sessions helped them integrate the experience and reinforce behavioral change.
This model demonstrates a broader shift in psychedelic research, which increasingly stresses the importance of “set and setting”—the psychological and environmental context in which the drug is administered.
The study also found that participants in the psilocybin group smoked significantly fewer cigarettes overall, even when they did not achieve complete abstinence. On average, their daily cigarette use was reduced by more than half compared to those in the nicotine patch group.
Importantly, the treatment appeared to be safe within the controlled conditions of the trial. No serious adverse events were reported. While participants receiving psilocybin did experience temporary increases in blood pressure and heart rate, along with headaches and other mild symptoms, these effects were closely monitored and resolved without long-term consequences.
That safety profile, combined with the treatment’s apparent effectiveness, raises the possibility that psilocybin could eventually move toward regulatory approval for smoking cessation, a prospect that would have seemed unlikely just a few years ago.
Still, researchers caution that the findings are preliminary. The study was relatively small, and participants were not blinded to their treatment group, a factor that could influence outcomes. Additionally, the sample lacked diversity and included a high proportion of individuals who had previously used psychedelics, which may limit how broadly the results can be applied.
There are also practical issues. Psilocybin-assisted therapy is far more resource-intensive than traditional treatments, requiring trained facilitators, extended therapy sessions, and controlled clinical environments. While this approach may yield better outcomes, scaling it for large-scale use offers a significant challenge.
Nevertheless, the results add to a growing body of evidence suggesting that psychedelics may have broad applications in treating addiction.
Previous studies have explored their potential in addressing alcohol and opioid use disorders, with similarly promising results. Taken together, the results point to what some researchers describe as a “transdiagnostic” effect, where a single intervention may be effective across multiple forms of addiction.
What makes this approach especially intriguing is that it does not rely on directly counteracting the addictive substance. Instead, it appears to operate at a higher level, possibly reshaping how individuals understand their behavior and their sense of self.
Traditional treatments often struggle because they address the symptoms of addiction, such as cravings or withdrawal, without fully resolving the underlying psychological drivers. Psilocybin, by contrast, may offer a way to disrupt those deeper patterns, creating an opportunity for lasting change.
The researchers argue that their findings justify further investigation, particularly in larger and more diverse populations. And if future studies verify these results, the implications could extend well beyond smoking.
The possibility of a treatment for addiction that can produce meaningful, long-term change after a single intervention is difficult to ignore. For now, psilocybin remains an experimental therapy. However, clinical trials like this suggest it may be moving closer to the mainstream, potentially revising how we approach one of the most persistent and deadly habits in modern society.
“In this pilot randomized clinical trial, administration of 1 dose of psilocybin with manualized CBT compared with nicotine patch treatment with CBT significantly increased long-term abstinence,” researchers conclude. “The current trial’s results suggest that psilocybin is a promising candidate for smoking cessation that should move forward in the FDA process toward potential approval.”
Tim McMillan is a retired law enforcement executive, investigative reporter and co-founder of The Debrief. His writing typically focuses on defense, national security, the Intelligence Community and topics related to psychology. You can follow Tim on Twitter: @LtTimMcMillan. Tim can be reached by email: tim@thedebrief.org or through encrypted email: LtTimMcMillan@protonmail.com